The European Medicines Agency has asked the drug manufacturers ozempic and vegovi to provide more information about possible links between their use and thyroid cancer. It has been reported Health News.
Newer blood sugar medications Ozempic and Wegovy have also become popular weight loss medications. Studies have shown that it allows you to lose up to 20% of the first kilo in a few months. The active ingredient in Ozempik and vegovi is semaglutide.
Last month, the European Medicines Agency (EMA), the European Union (EU) agency responsible for evaluating and overseeing pharmaceuticals, expressed concern about the possible risk of thyroid cancer in people taking semaglutide.
In a document published May 8, 2023, the EMA required that manufacturers of semaglutide (Novo Nordisk, AstraZeneca, Eli Lilly, and others) provide additional information on the drug by July 26, 2023.
Earlier in February, a study was published in the journal Diabetes Care showing that taking semaglutide for one to three years may increase the risk of all types of thyroid cancer (TC). However, these and other studies have not provided conclusive evidence of a causal relationship between semaglutide use and an increased risk of thyroid cancer.
Eli Lilly had previously acknowledged a possible link between semaglutide and RGS and is working with regulators to conduct new studies on the drug, Reuters reported.
The directions for use for Ozempic and vegovi inform consumers of potential side effects such as pancreatitis, gallbladder disease and kidney damage. Manufacturers also warn that semaglutide causes C-cell thyroid tumors in rodents, but it is not known whether this side effect occurs in humans.
ancient scientists discoveredthat taking certain medications during menopause can increase a woman’s risk of dementia by 21% or more.